Esco Ventures is pleased to announce the appointment of Prof. Moshe Hod as Clinical Advisor. Prof Moshe Hod shares the same vision as Esco Ventures. As Clinical Advisor, he will also be working with Carmentix, an Esco Ventures backed startup company developing a novel biomarker prognostic panel for preterm birth.
Prof. Moshe Hod is the President of the European Association of Perinatal Medicine (EAPM) as well as the Chairman of the International Federation of Obstetrics and Gynecology (FIGO) - Hyperglycemia In Pregnancy Working Group.Prof. Hod was Director of the Maternal Fetal Medicine Division at the Helen Schneider Women’s Hospital, Rabin Medical Center and Professor of Obstetrics and Gynecology at the Sackler Faculty of Medicine, Tel-Aviv University, Israel. He serves as a Chief Consultant in Perinatal Medicine to Clalit Health Services (HMO) and as the Director of Mor Women’s Health Center.
Prof. Moshe Hod served as the Chairman of the Medical Advisory Board and Medical Director of Global Medical Networks (GMN) developers of a technology to build patient-centric eHealth Networks (LifeOnKey®) and has served as the Chairman of the Medical Advisory Board of Rosetta Genomics(NASDAQ :ROSG), leader in the development of microRNA-based diagnostics and therapeutics.
Prof. Moshe Hod was trained in Obstetrics and Gynecology in Israel and later in Perinatal Medicine in the leading medical institutions: Hammersmith Hospital, the Royal Postgraduate Medical School, London, UK, Northwestern University Medical School in Chicago, and the University of Texas in San-Antonio, Texas, US. He has over 300 scientific publications published to date.